Cargando…
A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting
Lung-targeting drugs are thought to be potential therapies of refractory lung diseases by maximizing local drug concentrations in the lung to avoid systemic circulation. However, a major limitation in developing lung-targeted drugs is the acquirement of lung-specific ligands. Pulmonary surfactant pr...
Autores principales: | Wang, Shan-Mei, He, Xian, Li, Nan, Yu, Feng, Hu, Yang, Wang, Liu-Sheng, Zhang, Peng, Du, Yu-Kui, Du, Shan-Shan, Yin, Zhao-Fang, Wei, Ya-Ru, Mulet, Xavier, Coia, Greg, Weng, Dong, He, Jian-Hua, Wu, Min, Li, Hui-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403696/ https://www.ncbi.nlm.nih.gov/pubmed/25926731 http://dx.doi.org/10.2147/IJN.S77268 |
Ejemplares similares
-
Identification of a nanobody specific to human pulmonary surfactant protein A
por: He, Xian, et al.
Publicado: (2017) -
Erratum: Identification of a nanobody specific to a human pulmonary surfactant protein A
por: He, Xian, et al.
Publicado: (2017) -
Surfactant protein-A nanobody-conjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury
por: Li, Nan, et al.
Publicado: (2017) -
Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
por: Weng, Dong, et al.
Publicado: (2021) -
Screening for Differentially Expressed Proteins Relevant to the Differential Diagnosis of Sarcoidosis and Tuberculosis
por: Du, Shan-Shan, et al.
Publicado: (2015)